NASDAQ:GHDX - Genomic Health Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $72.70 +2.15 (+3.05 %) (As of 01/18/2019 04:00 PM ET)Previous Close$70.55Today's Range$70.33 - $73.6452-Week Range$30.04 - $92.18Volume423,108 shsAverage Volume354,730 shsMarket Capitalization$2.54 billionP/E Ratio7,270.00Dividend YieldN/ABeta0.73 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Genomic Health, Inc., a healthcare company, provides actionable genomic information to personalize cancer treatment decisions worldwide. It develops and commercializes genomic-based clinical laboratory services that analyze the underlying biology of cancer, allowing physicians and patients to make individualized treatment decisions. The company offers the Oncotype DX invasive breast cancer test that is used for early stage invasive breast cancer patients to predict the breast cancer recurrence and chemotherapy benefit. It also provides the Oncotype DX colon cancer test, which is used to predict the likelihood of colon cancer recurrence in patients with stage II disease, as well as for use in patients with stage III disease treated with oxaliplatin-containing adjuvant therapy. In addition, the company provides the Oncotype DX tests for patients with ductal carcinoma in situ, a pre-invasive form of breast cancer; the Oncotype DX prostate cancer test, which provides a genomic prostate score to predict disease aggressiveness in men with low risk disease, as well as used to enhance treatment decisions for prostate cancer patients in conjunction with the Gleason score or tumor grading; and Oncotype DX AR-V7 Nucleus Detect test for men with metastatic castration-resistant prostate cancer. The company offers its products through a network of distributors. Genomic Health, Inc. has collaboration agreement with Epic Sciences, Inc.; license and development agreement with Biocartis N.V.; license agreement with Cleveland Diagnostics, Inc.; and a research collaboration agreement with Janssen Pharmaceuticals. The company was founded in 2000 and is based in Redwood City, California. Receive GHDX News and Ratings via Email Sign-up to receive the latest news and ratings for GHDX and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Medical laboratories Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:GHDX Previous Symbol CUSIP37244C10 Webwww.genomichealth.com Phone650-556-9300Debt Debt-to-Equity RatioN/A Current Ratio4.89 Quick Ratio4.89Price-To-Earnings Trailing P/E Ratio7,270.00 Forward P/E Ratio68.58 P/E GrowthN/A Sales & Book Value Annual Sales$340.75 million Price / Sales7.71 Cash Flow$0.3606 per share Price / Cash Flow201.59 Book Value$5.41 per share Price / Book13.44Profitability EPS (Most Recent Fiscal Year)$0.01 Net Income$-3,850,000.00 Net Margins4.95% Return on Equity14.05% Return on Assets11.57%Miscellaneous Employees863 Outstanding Shares36,123,000Market Cap$2.54 billion OptionableOptionable Genomic Health (NASDAQ:GHDX) Frequently Asked Questions What is Genomic Health's stock symbol? Genomic Health trades on the NASDAQ under the ticker symbol "GHDX." How were Genomic Health's earnings last quarter? Genomic Health, Inc. (NASDAQ:GHDX) posted its earnings results on Tuesday, November, 6th. The medical research company reported $0.35 earnings per share for the quarter, topping analysts' consensus estimates of $0.07 by $0.28. The medical research company had revenue of $101.30 million for the quarter, compared to analyst estimates of $94.27 million. Genomic Health had a return on equity of 14.05% and a net margin of 4.95%. The firm's revenue was up 23.2% compared to the same quarter last year. During the same period in the previous year, the firm earned ($0.06) EPS. View Genomic Health's Earnings History. When is Genomic Health's next earnings date? Genomic Health is scheduled to release their next quarterly earnings announcement on Thursday, March 14th 2019. View Earnings Estimates for Genomic Health. What guidance has Genomic Health issued on next quarter's earnings? Genomic Health updated its FY18 earnings guidance on Tuesday, November, 6th. The company provided earnings per share guidance of $1.03-$1.08 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $0.53. The company issued revenue guidance of $389-$391 million, compared to the consensus revenue estimate of $380.74 million.Genomic Health also updated its FY 2018 guidance to $1.03-1.08 EPS. What price target have analysts set for GHDX? 10 equities research analysts have issued twelve-month price targets for Genomic Health's stock. Their predictions range from $33.00 to $86.00. On average, they anticipate Genomic Health's stock price to reach $56.4286 in the next year. This suggests that the stock has a possible downside of 22.4%. View Analyst Price Targets for Genomic Health. What is the consensus analysts' recommendation for Genomic Health? 10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Genomic Health in the last year. There are currently 8 hold ratings, 1 buy rating and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Genomic Health. Has Genomic Health been receiving favorable news coverage? News coverage about GHDX stock has been trending somewhat negative recently, according to InfoTrie Sentiment. The research group identifies negative and positive media coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Genomic Health earned a coverage optimism score of -1.0 on InfoTrie's scale. They also gave news coverage about the medical research company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an effect on the company's share price in the near term. Who are some of Genomic Health's key competitors? Some companies that are related to Genomic Health include ELEKTA AB/ADR (EKTAY), Guardant Health (GH), InVitae (NVTA), CareDx (CDNA), Natera (NTRA), Veracyte (VCYT), RadNet (RDNT), Celcuity (CELC), Enzo Biochem (ENZ), Miragen Therapeutics (MGEN), Psychemedics (PMD), Fulgent Genetics (FLGT), PotNetwork (POTN), First Choice Healthcare Solutions (FCHS) and OpGen (OPGN). Who are Genomic Health's key executives? Genomic Health's management team includes the folowing people: Ms. Kimberly J. Popovits, Chairman, CEO & Pres (Age 59)Dr. Steven Shak, Co-Founder, Chief Scientific Officer & Chief Medical Officer (Age 67)Mr. G. Bradley Cole, Chief Financial Officer (Age 62)Dr. Frederic G. Pla, Chief Operating Officer (Age 59)Mr. James J. Vaughn, Chief U.S. Commercial Officer (Age 55) Who are Genomic Health's major shareholders? Genomic Health's stock is owned by many different of institutional and retail investors. Top institutional shareholders include Copper Rock Capital Partners LLC (0.81%), Scout Investments Inc. (0.19%), Bowling Portfolio Management LLC (0.02%) and Meeder Asset Management Inc. (0.01%). Company insiders that own Genomic Health stock include Bros Advisors Lp Baker, Fred E Cohen, Frederic Pla, G Bradley Cole, James J Vaughn, Kimberly J Popovits, Laura Leber, Phillip G Febbo and Steven Shak. View Institutional Ownership Trends for Genomic Health. Which major investors are selling Genomic Health stock? GHDX stock was sold by a variety of institutional investors in the last quarter, including Scout Investments Inc., Bowling Portfolio Management LLC and Meeder Asset Management Inc.. Company insiders that have sold Genomic Health company stock in the last year include Bros Advisors Lp Baker, Fred E Cohen, Frederic Pla, G Bradley Cole, James J Vaughn, Kimberly J Popovits, Phillip G Febbo and Steven Shak. View Insider Buying and Selling for Genomic Health. Which major investors are buying Genomic Health stock? GHDX stock was bought by a variety of institutional investors in the last quarter, including Copper Rock Capital Partners LLC. View Insider Buying and Selling for Genomic Health. How do I buy shares of Genomic Health? Shares of GHDX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Genomic Health's stock price today? One share of GHDX stock can currently be purchased for approximately $72.70. How big of a company is Genomic Health? Genomic Health has a market capitalization of $2.54 billion and generates $340.75 million in revenue each year. The medical research company earns $-3,850,000.00 in net income (profit) each year or $0.01 on an earnings per share basis. Genomic Health employs 863 workers across the globe. What is Genomic Health's official website? The official website for Genomic Health is http://www.genomichealth.com. How can I contact Genomic Health? Genomic Health's mailing address is 301 PENOBSCOT DRIVE, REDWOOD CITY CA, 94063. The medical research company can be reached via phone at 650-556-9300 or via email at [email protected] MarketBeat Community Rating for Genomic Health (NASDAQ GHDX)Community Ranking: 2.2 out of 5 ( )Outperform Votes: 260 (Vote Outperform)Underperform Votes: 320 (Vote Underperform)Total Votes: 580MarketBeat's community ratings are surveys of what our community members think about Genomic Health and other stocks. Vote "Outperform" if you believe GHDX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GHDX will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 1/18/2019 by MarketBeat.com StaffFeatured Article: What is a Tariff?